Journal article · 2017 · Open access

Alzheimer's disease drug development pipeline: 2017

Jeffrey L. Cummings, Yadi Zhou, Yuxin Yang, Kate Zhong, Jorge Ramón Fonseca Cacho, Amanda Leisgang Osse, Feixiong Cheng

Alzheimer s & Dementia Translational Research & Clinical Interventions, 12(2), 367–384 · Published 24 May 2017 · DOI 10.1002/trc2.70251

Read the free full textCite this paper

In brief

“Alzheimer's disease drug development pipeline: 2017” is a 2017 journal article by Jeffrey L. Cummings and 6 co-authors, published in Alzheimer s & Dementia Translational Research & Clinical Interventions. OpenAlex counts 579 citations as of 15 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Alzheimer s & Dementia Translational Research & Clinical Interventions.

Citations
579
Most cited in
2018 (107)
Field-weighted impact
30.35
References
55
Authors
7

Abstract

INTRODUCTION: There is an urgent need to develop new treatments for Alzheimer's disease (AD) and to understand the drug development process for new AD therapies. METHODS: We assessed the agents in the AD pipeline as documented in clinicaltrials.gov for phase I, phase II, and phase III, accessed 1/5/2017. RESULTS: There are 105 agents in the AD treatment development pipeline, of which 25 agents are in 29 trials in phase I, 52 agents are in 68 trials in phase II, and 28 agents are in 42 trials in phase III. Seventy percent of drugs in the AD pipeline are disease-modifying therapies (DMTs). Fourteen percent are symptomatic cognitive enhancers, and 13% are symptomatic agents addressing neuropsychiatric and behavioral changes (2% have undisclosed mechanisms). Most trials are sponsored by the biopharmaceutical industry. Trials include patients with preclinical AD (cognitively normal with biomarker evidence of AD), prodromal AD (mild cognitive symptoms and biomarker evidence of AD), and AD dementia. Biomarkers are included in many drug development programs particularly those for DMTs. Thirteen of 46 phase II DMT trials have amyloid imaging as an entry criterion, and 10 of 28 phase III trials incorporate amyloid imaging for diagnosis and entry. A large number of participants are needed for AD clinical trials; in total, 54,073 participants are required for trials spanning preclinical AD to AD dementia. When compared with the 2016 pipeline, there are eight new agents in phase I, 16 in phase II, and five in phase III. DISCUSSION: The AD drug development pipeline has 105 agents divided among phase I, phase II, and phase III. The trials include a wide range of clinical trial populations, many mechanisms of action, and require a substantial number of clinical trial participants. Biomarkers are increasingly used in patient identification and as outcome measures, particularly in trials of DMTs.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Cummings, J. L., Zhou, Y., Yang, Y., Zhong, K., Cacho, J. R. F., Osse, A. L., & Cheng, F. (2017). Alzheimer's disease drug development pipeline: 2017. Alzheimer s & Dementia Translational Research & Clinical Interventions, 12(2), 367–384. https://doi.org/10.1002/trc2.70251

MLA 9

Cummings, Jeffrey L., et al. “Alzheimer's disease drug development pipeline: 2017.” Alzheimer s & Dementia Translational Research & Clinical Interventions, vol. 12, no. 2, 2017, pp. 367–384. https://doi.org/10.1002/trc2.70251.

Chicago

Cummings, Jeffrey L., Yadi Zhou, Yuxin Yang, Kate Zhong, Jorge Ramón Fonseca Cacho, Amanda Leisgang Osse, and Feixiong Cheng. 2017. “Alzheimer's disease drug development pipeline: 2017.” Alzheimer s & Dementia Translational Research & Clinical Interventions 12 (2): 367–384. https://doi.org/10.1002/trc2.70251.

Harvard

Cummings, J. L. et al. (2017) ‘Alzheimer's disease drug development pipeline: 2017’, Alzheimer s & Dementia Translational Research & Clinical Interventions, 12(2), pp. 367–384. doi:10.1002/trc2.70251.

IEEE

J. L. Cummings et al., “Alzheimer's disease drug development pipeline: 2017,” Alzheimer s & Dementia Translational Research & Clinical Interventions, vol. 12, no. 2, pp. 367–384, 2017, doi: 10.1002/trc2.70251.

BibTeX

@article{cummings2017alzheimer,
  title     = {{Alzheimer's disease drug development pipeline: 2017}},
  author    = {Cummings, Jeffrey L. and Zhou, Yadi and Yang, Yuxin and Zhong, Kate and Cacho, Jorge Ramón Fonseca and Osse, Amanda Leisgang and Cheng, Feixiong},
  journal   = {Alzheimer s \& Dementia Translational Research \& Clinical Interventions},
  year      = {2017},
  volume    = {12},
  number    = {2},
  pages     = {367--384},
  doi       = {10.1002/trc2.70251},
  url       = {https://doi.org/10.1002/trc2.70251}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201777
2018107107
20199393
20205454
20215757
20227171
20235454
20244848
20255555
20263131

Its field-weighted citation impact is 30.35: it has been cited 30.35 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • Alzheimer's disease
  • drug development pipeline
  • clinical trials
  • disease-modifying therapy
  • prodromal Alzheimer's disease
  • preclinical Alzheimer's disease
  • amyloid imaging
  • biomarkers

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Cummings, J. L., Zhou, Y., Yang, Y., Zhong, K., Cacho, J. R. F., Osse, A. L., & Cheng, F. (2017). Alzheimer's disease drug development pipeline: 2017. Alzheimer s & Dementia Translational Research & Clinical Interventions, 12(2), 367–384. https://doi.org/10.1002/trc2.70251

How many times has this paper been cited?

579 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at Alzheimer s & Dementia Translational Research & Clinical Interventions.

Who wrote this paper?

Jeffrey L. Cummings, Yadi Zhou, Yuxin Yang, Kate Zhong, Jorge Ramón Fonseca Cacho, Amanda Leisgang Osse, Feixiong Cheng.

What is the DOI of this paper?

10.1002/trc2.70251. The permanent link is https://doi.org/10.1002/trc2.70251.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.